SMMT Summit Therapeutics PLC
P/E
--
Forward P/E
3.722
Price/Sales
3891.31
Beta
-1.314
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Summit Therapeutics rated Buy, citing short squeeze potential and upcoming catalysts
Seeking Alpha initiated coverage on Summit Therapeutics with a cautious Buy rating. The analysis describes the company as a volatile, single-asset entity...
🟢 Summit Therapeutics PLC up 4.03% on recent $50M insider investment and withdrawn equity offering
Summit Therapeutics PLC is trading at $14.44 (+4.03%) today, fueled by a series of recent positive company-specific developments. • A director, Robert W....